Trial Profile

Multiple-dose exenatide XTEN vs exenatide in type 2 diabetes mellitus.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exenatide (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions

Most Recent Events

09 Jun 2012 This trial is still being planned, according to a Diartis Pharmaceuticals media release.
16 Feb 2011 This trial is expected to start in 2011.
22 Jun 2010 This study is planned to begin in the fourth quarter of 2010, according to a Versartis media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com